Northern Trust’s AN2 Therapeutics ANTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.12M Sell
209,978
-4,943
-2% -$26.2K ﹤0.01% 3368
2026
Q2
$1.04M Buy
214,921
+171,725
+398% +$739K ﹤0.01% 3451
2026
Q1
$148K Hold
43,196
– – ﹤0.01% 4021
2025
Q4
$49.2K Hold
43,196
– – ﹤0.01% 4280
2025
Q3
$54.9K Hold
43,196
– – ﹤0.01% 4269
2025
Q2
$45.8K Hold
43,196
– – ﹤0.01% 4245
2025
Q1
$58.7K Hold
43,196
– – ﹤0.01% 4209
2024
Q4
$59.6K Buy
43,196
+10,601
+33% +$12.9K ﹤0.01% 4241
2024
Q3
$34.9K Hold
32,595
– – ﹤0.01% 4268
2024
Q2
$70.1K Sell
32,595
-3,768
-10% -$8.97K ﹤0.01% 4136
2024
Q1
$118K Buy
36,363
+3,313
+10% +$36K ﹤0.01% 4033
2023
Q4
$677K Buy
33,050
+16,415
+99% +$275K ﹤0.01% 3442
2023
Q3
$267K Buy
+16,635
New +$188K ﹤0.01% 3710
2023
Q2
– Sell
-76,134
Closed -$751K – 4535
2023
Q1
$751K Sell
76,134
-4,684
-6% -$52.1K ﹤0.01% 3314
2022
Q4
$770K Buy
80,818
+43,379
+116% +$581K ﹤0.01% 3355
2022
Q3
$650K Buy
37,439
+1,042
+3% +$12.1K ﹤0.01% 3427
2022
Q2
$282K Buy
+36,397
New +$482K ﹤0.01% 3750

Other funds holding ANTX

Northern Trust's ANTX Position: Q3 2026 in Review

Northern Trust reduced its AN2 Therapeutics (ANTX) stake by 2.3% in Q3 2026, selling an estimated $26.2K and leaving 209,978 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #3368.

Northern Trust first reported a position in ANTX in Q2 2022 and has held it in 17 quarters since. 85 funds tracked by Wall St. Rank hold ANTX as of Q3 2026.

  • Northern Trust held 209,978 shares of AN2 Therapeutics worth $1.12M as of Q3 2026.
  • Northern Trust sold 4,943 AN2 Therapeutics shares in Q3 2026, an estimated $26.2K.
  • AN2 Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q3 2026, its #3368 holding.
  • Northern Trust first reported a position in AN2 Therapeutics in Q2 2022 and has held it in 17 quarters since.
  • 85 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q3 2026.

Based on Northern Trust's 13F filing for Q3 2026, filed 16 Nov 2026.